FIG 3.

URMC-099 promotes ZIKV infection in vivo. (A) Experimental scheme of the effect of URMC-099 in a neonatal mouse model of ZIKV infection. The ZIKV SZ01 strain (1 μl virus stock per animal) was intracerebrally injected into neonatal BALB/c mice on day 0 after birth. URMC-099 (5 mg/kg) was supplemented together with ZIKV on day 0. The same volume of PBS was used as a control. The infected brains were isolated for analysis on days 2 and 3. (B to E) Viral envelope protein levels and the viral RNA load in whole brains (n = 4) from ZIKV-infected neonatal mice were determined by Western blotting and qRT-PCR on day 2 (B and D) and day 3 (C and E). Experiments were performed twice, and the data are presented as the mean ± standard error of the mean (SEM) from one independent experiment. Statistical analysis was performed using an unpaired, two-tailed t test. **, P < 0.01; ***, P < 0.001.